• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.

作者信息

Han Xu, Nieman Marvin T

机构信息

From the Department of Pharmacology, Case Western Reserve University, Cleveland, OH.

出版信息

Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):287-289. doi: 10.1161/ATVBAHA.117.310550.

DOI:10.1161/ATVBAHA.117.310550
PMID:29367229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5788293/
Abstract
摘要

相似文献

1
PAR4 (Protease-Activated Receptor 4): PARticularly Important 4 Antiplatelet Therapy.蛋白酶激活受体4（PAR4）：抗血小板治疗中尤为重要的4号受体
Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):287-289. doi: 10.1161/ATVBAHA.117.310550.
2
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.阻断蛋白酶激活受体 4（PAR4）可提供强大的抗血栓活性，同时出血风险低。
Sci Transl Med. 2017 Jan 4;9(371). doi: 10.1126/scitranslmed.aaf5294.
3
Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.阻断血小板介导的血栓形成中的蛋白酶激活受体1-4异二聚体
Circulation. 2006 Mar 7;113(9):1244-54. doi: 10.1161/CIRCULATIONAHA.105.587758. Epub 2006 Feb 27.
4
Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets.联合阻断凝血酶阴离子结合外显子-1 和 PAR4 可在人血小板中产生协同的抗血小板作用。
Thromb Haemost. 2011 Jan;105(1):88-95. doi: 10.1160/TH10-05-0305. Epub 2010 Nov 5.
5
Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.通过分隔的环核苷酸作用对人血小板中蛋白酶激活受体（PAR）1和PAR4信号传导的调节
J Pharmacol Exp Ther. 2007 Aug;322(2):778-88. doi: 10.1124/jpet.107.121830. Epub 2007 May 24.
6
Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.在流动和静态条件下评估 PAR1 和 PAR4 拮抗剂的抗血栓作用。
Thromb Res. 2014 Jan;133(1):66-72. doi: 10.1016/j.thromres.2013.10.037. Epub 2013 Oct 31.
7
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.蛋白酶激活受体1（PAR1）拮抗剂可抑制凝血酶诱导的血小板活化，而使PAR4介导的反应保持完整。
Platelets. 2015;26(3):236-42. doi: 10.3109/09537104.2014.902924. Epub 2014 Apr 21.
8
Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides.蛋白酶激活受体4（PAR4）：PAR4衍生肽对大鼠血小板聚集的激活与抑制作用
Can J Physiol Pharmacol. 2001 May;79(5):439-42.
9
Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques.食蟹猴中蛋白酶激活受体1和4拮抗剂的抗血栓形成益处及出血风险差异概况
Thromb Res. 2016 Sep;145:133-9. doi: 10.1016/j.thromres.2016.06.007. Epub 2016 Jun 11.
10
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.蛋白酶激活受体1和4介导凝血酶对人血小板的激活作用。
J Clin Invest. 1999 Mar;103(6):879-87. doi: 10.1172/JCI6042.

引用本文的文献

1
Endothelial protease-activated receptor 4: impotent or important?内皮蛋白酶激活受体4：无作用还是重要？
Front Cardiovasc Med. 2025 Jan 28;12:1541879. doi: 10.3389/fcvm.2025.1541879. eCollection 2025.
2
Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling.血管平滑肌细胞中的蛋白酶激活受体：血栓炎症与血管重塑之间的桥梁。
Cell Commun Signal. 2025 Jan 31;23(1):57. doi: 10.1186/s12964-025-02066-6.
3
PARticularly Forceful: PAR1 Drives Glomerular Mesangial Cell Contractility.特别有力：PAR1驱动肾小球系膜细胞收缩。
Function (Oxf). 2024 Nov 20;5(6). doi: 10.1093/function/zqae044.
4
Mechanisms Underlying Dichotomous Procoagulant COAT Platelet Generation-A Conceptual Review Summarizing Current Knowledge.双重促凝 COAT 血小板生成的潜在机制——概述当前知识的概念性综述。
Int J Mol Sci. 2022 Feb 25;23(5):2536. doi: 10.3390/ijms23052536.
5
Genetic deletion of platelet PAR4 results in reduced thrombosis and impaired hemostatic plug stability.血小板 PAR4 的基因缺失可导致血栓形成减少和止血栓稳定性受损。
J Thromb Haemost. 2022 Feb;20(2):422-433. doi: 10.1111/jth.15569. Epub 2021 Nov 10.
6
Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses.肝素和比伐卢定对凝血酶诱导的血小板活化的影响：PAR信号的差异调节驱动不同的促血栓形成反应。
Front Cardiovasc Med. 2021 Sep 29;8:717835. doi: 10.3389/fcvm.2021.717835. eCollection 2021.
7
Platelet Activation and Plasma Levels of Furin Are Associated With Prognosis of Patients With Coronary Artery Disease and COVID-19.血小板活化和弗林蛋白酶的血浆水平与冠心病和 COVID-19 患者的预后相关。
Arterioscler Thromb Vasc Biol. 2021 Jun;41(6):2080-2096. doi: 10.1161/ATVBAHA.120.315698. Epub 2021 Apr 29.
8
The domino effect triggered by the tethered ligand of the protease activated receptors.由蛋白酶激活受体的连接配体引发的级联反应。
Thromb Res. 2020 Dec;196:87-98. doi: 10.1016/j.thromres.2020.08.004. Epub 2020 Aug 4.
9
The Roles of GRKs in Hemostasis and Thrombosis.GRKs 在止血和血栓形成中的作用。
Int J Mol Sci. 2020 Jul 28;21(15):5345. doi: 10.3390/ijms21155345.
10
PAR4 activation involves extracellular loop 3 and transmembrane residue Thr153.PAR4 的激活涉及细胞外环 3 和跨膜残基 Thr153。
Blood. 2020 Nov 5;136(19):2217-2228. doi: 10.1182/blood.2019004634.

本文引用的文献

1
New developments in anticoagulants: Past, present and future.新型抗凝药物的进展：过去、现在和未来。
Thromb Haemost. 2017 Jun 28;117(7):1283-1288. doi: 10.1160/TH16-10-0807. Epub 2017 Jun 8.
2
Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.阻断蛋白酶激活受体 4（PAR4）可提供强大的抗血栓活性，同时出血风险低。
Sci Transl Med. 2017 Jan 4;9(371). doi: 10.1126/scitranslmed.aaf5294.
3
Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.抑制蛋白酶激活受体 4 可削弱人血液血栓形成过程中的血小板促凝活性。
J Thromb Haemost. 2016 Aug;14(8):1642-54. doi: 10.1111/jth.13293. Epub 2016 Jun 22.
4
Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.2014年美国食品药品监督管理局心血管和肾脏药物咨询委员会关于vorapaxar的会议概述。
Circulation. 2014 Oct 7;130(15):1287-94. doi: 10.1161/CIRCULATIONAHA.114.011471.
5
Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.靶向人蛋白酶激活受体 4 的阴离子区域可抑制血小板聚集和血栓形成，而不干扰止血。
J Thromb Haemost. 2014 Aug;12(8):1331-41. doi: 10.1111/jth.12619. Epub 2014 Jun 27.
6
Differential signaling by protease-activated receptors: implications for therapeutic targeting.蛋白酶激活受体的差异信号传导：对治疗靶点的影响。
Int J Mol Sci. 2014 Apr 11;15(4):6169-83. doi: 10.3390/ijms15046169.
7
Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.Vorapaxar 用于预防既往心肌梗死患者的血栓事件复发：TRA 2°P-TIMI 50 试验的预先设定亚组分析。
Lancet. 2012 Oct 13;380(9850):1317-24. doi: 10.1016/S0140-6736(12)61269-0. Epub 2012 Aug 26.
8
Vorapaxar in the secondary prevention of atherothrombotic events.沃拉帕沙用于动脉粥样血栓事件的二级预防。
N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.
9
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.凝血酶受体拮抗剂沃拉帕沙在急性冠脉综合征中的应用。
N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.
10
Interaction of thrombin with PAR1 and PAR4 at the thrombin cleavage site.凝血酶在凝血酶裂解位点与蛋白酶激活受体1（PAR1）和蛋白酶激活受体4（PAR4）的相互作用。
Biochemistry. 2007 Jul 24;46(29):8603-10. doi: 10.1021/bi700597p. Epub 2007 Jun 27.